Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ACADIA Pharmaceuticals Inc ACAD

Healthcare Biotechnology
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders... see more

Recent & Breaking News (NDAQ:ACAD)

Acadia Pharmaceuticals to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022

Business Wire March 3, 2022

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

Business Wire February 28, 2022

Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer's Disease Psychosis

Business Wire February 16, 2022

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

Business Wire February 14, 2022

Acadia Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022

Business Wire February 11, 2022

Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases

Business Wire January 10, 2022

Acadia Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

Business Wire December 22, 2021

Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin)

Business Wire December 20, 2021

Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer

Business Wire December 14, 2021

Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome

Business Wire December 6, 2021

The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of Schizophrenia

Business Wire December 1, 2021

Acadia Pharmaceuticals and StoryCorps Collaborate to Launch Yours, Truly - a Multicultural Storytelling Campaign to Bring Greater Awareness to Parkinson's Disease Non-Motor Symptoms

Business Wire November 16, 2021

Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results

Business Wire November 8, 2021

Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data at Psych Congress 2021

Business Wire November 2, 2021

Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial

Business Wire November 1, 2021

Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021

Business Wire October 27, 2021

Acadia Pharmaceuticals to Present Data on Pimavanserin in Patients with Parkinson's Disease Dementia with Psychosis from the HARMONY trial at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Business Wire October 25, 2021

Acadia Pharmaceuticals to Present at Upcoming Investor Conferences

Business Wire September 2, 2021

Acadia Pharmaceuticals Announces Executive Leadership Change

Business Wire September 1, 2021

Selling The News In Acadia Pharmaceuticals

Benzinga.com  October 6, 2017